Advancements of ALK inhibition of non-small cell lung cancer: a literature review.
Victor Zia, Csongor György Lengyel, Carla Chizuru Tajima...
https://pubmed.ncbi.nlm.nih.gov/37577315/Actively Recruiting
Led by Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Updated on 2026-06-08
24
Participants Needed
1
Research Sites
35 weeks
Total Duration
Researchers are evaluating whether vortioxetine, an antidepressant with cognitive-enhancing effects, can reduce neurological and cognitive side effects caused by lorlatinib in patients with non-small cell lung cancer NSCLC that have ALK or ROS1 gene rearrangements. Lorlatinib is a targeted cancer therapy effective against these cancers but causes neuropsychological adverse events like cognitive impairment, mood changes, and speech problems in many patients. This observational study focuses on adults receiving lorlatinib who develop these side effects. Twenty-four adult patients with ALKROS1-positive NSCLC who are prescribed vortioxetine 10-20 mg per day as part of their standard care will be followed. The study documents changes in cognitive function, mood, and quality of life over multiple time points at the start, week 6, week 12, and month 6. Patients will continue their usual lorlatinib treatment while being monitored for how vortioxetine affects their neurological symptoms. Participants will undergo comprehensive neuropsychological testing and quality-of-life questionnaires at these intervals to measure various cognitive domains such as psychomotor speed, attention, memory, language, and executive function. Depressive symptoms, functional capacity, work limitations, and tumor response to lorlatinib will also be assessed. Adverse events will be monitored throughout the study and for 30 days after the last visit. The study lasts at least six months, allowing detailed observation of cognitive and mood changes during vortioxetine use.
CONDITIONS
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
F
Felipe Canro, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants are observed while receiving lorlatinib and initiating vortioxetine as part of routine care. Neuropsychological tests and questionnaires are completed to assess cognitive function and quality of life.
Visits at Baseline, Week 6, Week 12, and Months 1, 2, 3, 6, and 12
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Victor Zia, Csongor György Lengyel, Carla Chizuru Tajima...
https://pubmed.ncbi.nlm.nih.gov/37577315/Deepa Rangachari, Norihiro Yamaguchi, Paul A VanderLaan...
https://pubmed.ncbi.nlm.nih.gov/25682925/Grace Chen, Astrid-Maria Højer, Johan Areberg...
https://pubmed.ncbi.nlm.nih.gov/29189941/Ludger Sellmann, Klaus Fenchel, Wolfram C M Dempke
https://pubmed.ncbi.nlm.nih.gov/26207209/Ibiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist...
https://pubmed.ncbi.nlm.nih.gov/35584349/Julien Mazieres, Laura Iadeluca, Alice T Shaw...
https://pubmed.ncbi.nlm.nih.gov/36410210/Pirathiv Kugathasan, Jessica Waller, Ligia Westrich...
https://pubmed.ncbi.nlm.nih.gov/27678087/Donghong He, Amy W Lasek
https://pubmed.ncbi.nlm.nih.gov/31734646/Rafael Parra-Medina, Juan Pablo Castañeda-González, Luisa Montoya...
https://pubmed.ncbi.nlm.nih.gov/37729688/Alexandra M Vaiana, Yidong Chen, Jonathan Gelfond...
https://pubmed.ncbi.nlm.nih.gov/37788996/Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Lead Sponsor